CTOs on the Move

Foundations Associates

www.dualdiagnosis.org

 
Foundations Associates is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Brentwood, TN. To find more information about Foundations Associates, please visit www.dualdiagnosis.org
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

uBiome

uBiome is the leading microbial genomics company. We are pioneering a new era of microbiome-based precision medicine. We allow doctors, patients, and citizen scientists to learn about the human microbiome with unprecedented accuracy and speed.

Maryland Wellness

Maryland Wellness is an Outpatient Mental Health Clinic (OMHC) that helps individuals achieve their mental health and life goals. They provide reduced or no out of pocket cost services, including case management/PRP, therapy, psychiatry and addictions ...

Epoch Senior Living

EPOCH offers a 401(k) Retirement Savings Plan, with a variety of 25 fund options ranging from low to high risk, to choose from.

War Memorial Hospital

War Memorial Hospital is a Sault Sainte Marie, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.